Michael Bös

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Daniel Lamarre, Paul C. Anderson, Murray D. Bailey et al. · Nature · 2003 · 913 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential

Joel R. Martin, Michael Bös, F. Jenck et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 334 citations

Medicine, Medicinal Chemistry, Pharmacology +15

Influence of the 5-HT₆Receptor on Acetylcholine Release in the Cortex:  Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5-HT₆Receptor Antagonist

Claus Riemer, Edilio Borroni, Bernard Levet‐Trafit et al. · Journal of Medicinal Chemistry · 2003 · 191 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1

Lee D. Fader, Éric Malenfant, Mathieu Parisien et al. · ACS Medicinal Chemistry Letters · 2014 · 180 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT₆ receptors

Andrew J. Sleight, Frank Boess, Michael Bös et al. · British Journal of Pharmacology · 1998 · 179 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14